Pharmaceutical Position Paper 2015/2016 - 制药工作组建议书2015/2016 Go back »

Download


The Pharmaceutical Working Group represents over 60 foreign pharmaceutical manufacturing companies operating in China. The working group encourages government policies that support the creation of a
sustainable system that fosters innovation and healthy growth of the pharmaceutical industry as a whole, while improving patient access to innovative, highquality medicines, in line with China's declared strategic
objectives for the healthcare sector. Policies related to intellectual property (IP), pricing and reimbursement are the most potentially useful tools for rewarding quality and safety while creating incentives for domestic
and multinational companies alike to bring innovative medicines to the Chinese market. The working group supports the establishment of a transparent regulatory environment to solicit comments and participation from the pharmaceutical industry (both local and foreign) before formal policies on issues such as pricing, reimbursement and intellectual property rights (IPR) are announced.

Related documents

European Business in China Position Paper 2021/2022 - 欧盟企业在中国建议书2021/2022

Executive Position Paper 2021/2022 - 欧盟企业在中国建议书2021/2022-总体建议

Executive Position Paper 2020/2021 - 欧盟企业在中国建议书2020/2021

Related EURObiz articles